M G Kris

Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors.

M. Kris, T. Chou, V. Miller, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSS).

M. Kris, R. Gralla, P. Hollen, 1993, European journal of cancer.

Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers.

C. Sima, C. Rudin, M. Kris, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

M. Kris, H. Scher, V. Miller, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing.

M. Ladanyi, M. Kris, M. Arcila, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC).

G. Giaccone, A. Iafrate, C. Rudin, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.

M. Kris, J. Rigas, P. Francis, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.